Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431)

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 2927-2935

  Moore, Stephen R ^a   Persons, Diane L ^b   Sosman, Jeffrey A ^c   Bobadilla, Dolores ^a   Bedell, Victoria ^a   Smith, David D ^a   R wolman, Sandra ^d   J tuthill, Ralph ^e   Moon, Jim ^f   Sondak, Vernon K ^g   Slovak, Marilyn L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f Statistical Center   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CCND3 GENE; CDKN2A GENE; CHROMOSOME 7; CHROMOSOME 9P; COMPARATIVE GENOMIC HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE LOCUS; GENE LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MET GENE; METASTASIS; NEDD9 GENE; ONCOGENE MYC; PRIORITY JOURNAL; WISP3 GENE; CHROMOSOME ANALYSIS; DNA MICROARRAY; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETICS; METHODOLOGY; REPRODUCIBILITY;

CYTOGENETIC ANALYSIS; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MELANOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 49649092403     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4068     Document Type: Article

References (52)

1. Jemal A, Siegel R.Ward E, et al. Cancer statistics. CA Cancer J Clin 2008:58:71 -96.
2. Lewis TB, Robison JE, Bastien R, et al Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer 2005;104:1678-86.
3. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev2006;20:2149-82.
4. Casorzo L, Luzzi C, Nardacchione A, Picciotto F, Pisacane A, Risio M. Fluorescence in situ hybridization (FISH) evaluation of chromosomes 6, 7, 9 and 10 throughout human melanocytic tumorigenesis. Melanoma Res 2005;15:155-60.
5. Glatz-Krieger K, Pache M.Tapia C, et al Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected byfluorescence in situ hybridization. Virchows Arch 2006:449:328- 33
6. Hoglund M, Gisselsson D, Hansen GB. et al. Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004;108:57 - 65.
7. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007;67:2632 - 42.
8. Jonsson G, Dahl C, Staaf J, et al Genomic profiling of malignant melanoma using tiling-resolution array CGH. Oncogene 2007:108:57 - 65.
9. Nowak NJ, Miecznikowski J, Moore SR, et al. Challenges in array CGH for the analysis of cancer sam-pies. Genet Med 2007,9:585 - 95
10. Cowell JK, Nowak NJ High-resolution analysis of genetic events in cancer cells using bacterial artificial chromosome arrays and comparative genome hybridization Adv Cancer Res 2003:90:91-125
11. Olshen AB.Venkatraman ES, Lucito R.Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72.
12. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006;444:444-54.
13. Fiegler H, Geigl JB, Langer S, et al. High resolution array-CGH analysis of single cells. Nucleic Acids Res 2007;35:e15.
14. Duesberg P, Li R, Fabarius A, Hehlmann R. The chromosomal basis of cancer. Cell Oncol 2005;27: 293-318.
15. Kent WJ, Sugnet CW, FureyTS, et al. The human genome browser at UCSC. Genome Res 2002;12: 996-1006.
16. Lee J, BeliakoffJ, Sun Z.The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res 2007;35:4523-34.
17. 2/M phase and delays tumor growth in mice. Int J Cancer 2003;103:606-15.
18. Jönsson G. Dahl C, Staaf J, et al. Genomic profiling of malignant melanoma using tiling-resolution array-CGH. Oncogene 2007;26:4738-48.
19. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW.Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 1998;22:157-63.
20. Puig S, Castro J, Ventura PJ, et al. Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases. Melanoma Res 2000;10:231 -6.
21. Fargnoli MC, Argenziano G, Zalaudek I, Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther 2006;6:657-70.
22. Dissanayake SK, Wade M, Johnson CE, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007;282:17259-71.
23. Kim M, Gans JD, Nogueira C, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006;125:1269-81.
24. Cheng SL, Huang-Liu R, Sheu JN, Chen ST, Sinchaikul S.Tsay G J. Toxicogenomics of A375 human malignant melanoma cells. Pharmacogenomics 2007;8:1017-36.
25. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54.
26. Tonoli H, Barrett JC. CD82 metastasis suppressor gene: a potential target for new therapeutics? Trends Mol Med 2005;11:563-70.
27. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851 -7.
28. Sosman JA, Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 2006;12:2376-83s.
29. Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 2005;10:153-63.
30. Shih leM, Wang TL. Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82.
31. Garraway LA.Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
32. McGill GG, Horstmann M, Widlund HR, et al. BCL2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002;109:707-18.
33. Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 2003;163:333-43.
34. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002;1:279-88.
35. Trudel S, Stewart AK, Rom E, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006;107:4039-46.
36. Potti A, Ganti AK, Foster H, et al. Immunohisto-chemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overex-pression in soft tissue sarcomas. Anticancer Res 2004;24:333-7.
37. 1S progression. J Biol Chem 2006;281:25644-51.
38. Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000;6:3614-20.
39. Kleer CG, Zhang Y, Pan Q, et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 2004;6:110-5.
40. Zhang Y, Pan Q, Zhong H, Merajver SD, Kleer CG. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res 2005;7:1080-9.
41. Clark EA, GolubTR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532-5.
42. Nelson MA, Radmacher MD, Simon R, et al. Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases. Cancer Genet Cytogenet 2000;122:101 -9.
43. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-45.
44. Koynova D, Jordanova E, Kukutsch N, van der Velden P.Toncheva D, Gruis N. Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma. J Cancer Res Clin Oncol 2007;133:117-23.
45. Busam KJ, Jungbluth AA. Melan-A, a new melanocyte differentiation marker. AdvAnat Pathol 1999;6:12-8.
46. Talantov D, Mazumder A,Yu JX, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005;11:7234-42.
47. Takaoka A, Hinoda Y, Sato S, et al. Reduced invasive and metastatic potentials of KAI1 -transfected melanoma cells. Jpn J Cancer Res 1998;89:397-404.
48. Goldberg EK, Glendening JM, Karanjawala Z, et al. Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletion analysis. Am J Hum Genet 2000;67:417-31.
49. RothhammerT, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005;65: 448-56.
50. Torlakovic EE, Bilalovic N, Nesland JM.Torlakovic G, Florenes VA. Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis. Mod Pathol 2004;17:1400-6.
51. Fujimoto A, Takeuchi H, Taback B, et al. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 2004;64:2245-50.
52. Niedojadlo K, Labedzka K, Lada E, Milewska A, Chwirot BW. Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi. Pigment Cell Res 2006:19:43-50.